ArticleOncogene2008
MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer.
Article in Oncogene, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 150 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
150 citing papers in PubMed, 2 syntheses or guidelines pooled it, 287 citations in OpenAlex.
- Top 100 most-cited articles on apoptosis of non-small cell lung cancer over the past two decades: a bibliometrics analysis.Frontiers in immunology · 2024Pooled it
- The role of microRNA in castration-resistant prostate cancer.Urologic oncology · 2014Pooled it
- Current Evidence Supporting the Role of miRNA as a Biomarker for Lung Cancer Diagnosis Through Exhaled Breath Condensate Collection: A Narrative Review.Life (Basel, Switzerland) · 2025Review
- Review
- Editorial Expression of Concern: MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer.Oncogene · 2024Article
- microRNAs in exhaled breath condensate for diagnosis of lung cancer in a resource-limited setting: a concise review.Breathe (Sheffield, England) · 2023Review
- MicroRNAs as Potential Biomarkers of Environmental Exposure to Polycyclic Aromatic Hydrocarbons and Their Link with Inflammation and Lung Cancer.International journal of molecular sciences · 2023Review
- MiR-590-5p promotes cisplatin resistance via targeting hMSH2 in ovarian cancer.Molecular biology reports · 2023Article
- The Small RNA Landscape in NSCLC: Current Therapeutic Applications and Progresses.International journal of molecular sciences · 2023Review
- Potential role of saffron and its components on miRNA levels in various disorders, a comprehensive review.Iranian journal of basic medical sciences · 2023Review
- Review
- Role of microRNAs in response to cadmium chloride in pancreatic ductal adenocarcinoma.Archives of toxicology · 2022Article
- Correction: MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer.PloS one · 2022Article
- Cotargeting of miR-126-3p and miR-221-3p inhibits PIK3R2 and PTEN, reducing lung cancer growth and metastasis by blocking AKT and CXCR4 signalling.Molecular oncology · 2021Article
- MicroRNAs: The Link between the Metabolic Syndrome and Oncogenesis.International journal of molecular sciences · 2021Review
- Targeting Epigenetics in Lung Cancer.Cold Spring Harbor perspectives in medicine · 2021Review
- MiRNAs as Anti-Angiogenic Adjuvant Therapy in Cancer: Synopsis and Potential.Frontiers in oncology · 2021Review
- miR-26b enhances the sensitivity of hepatocellular carcinoma to Doxorubicin via USP9X-dependent degradation of p53 and regulation of autophagy.International journal of biological sciences · 2021Article
- MicroRNAs: potential biomarkers for diagnosis and prognosis of different cancers.Translational cancer research · 2020Review
- Advances of exosome isolation techniques in lung cancer.Molecular biology reports · 2020Review
90 more citing papers are in PubMed but not listed here.
Corrections and comments
- Expression of concern · 2024-02-28Concerns/Issues about Data · Concerns/Issues about Image · Duplication of/in Image · Error in Image · Euphemisms for Duplication · Objections by Author(s) · Upgrade/Update of Prior Notice(s) ·
- Erratum issued
- Expression of concern
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To define novel pathways that regulate susceptibility to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) in non-small cell lung cancer (NSCLC), we have performed genome-wide expression profiling of microRNAs (miRs). We show that in TRAIL-resistant NSCLC cells, levels of different miRs are increased, and in particular, miR-221 and -222. We demonstrate that these miRs impair TRAIL-dependent apoptosis by inhibiting the expression of key functional proteins. Indeed, transfection with anti-miR-221 and -222 rendered CALU-1-resistant cells sensitive to TRAIL. Conversely, H460-sensitive cells treated with -221 and -222 pre-miRs become resistant to TRAIL. miR-221 and -222 target the 3'-UTR of Kit and p27(kip1) mRNAs, but interfere with TRAIL signaling mainly through p27(kip1). In conclusion, we show that high expression levels of miR-221 and -222 are needed to maintain the TRAIL-resistant phenotype, thus making these miRs as promising therapeutic targets or diagnostic tool for TRAIL resistance in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.